TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR
申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
公开号:EP3858832A1
公开(公告)日:2021-08-04
Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
公开了一种三氟甲基取代的磺酰胺类 BCL-2 选择性抑制剂,特别是公开了一种式 I 的化合物、其立体异构体或药学上可接受的盐、其制备方法及其药物组合物。还公开了所述化合物及其药物组合物治疗抗凋亡 BCL-2 相关疾病(如癌症)的用途。
[EN] METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR<br/>[FR] INHIBITEUR DE BCL-2 SÉLECTIF À BASE DE SULFONAMIDE DISUBSTITUÉ CONTENANT DU MÉTHYLE ET DU TRIFLUOROMÉTHYLE<br/>[ZH] 包括甲基和三氟甲基的双取代磺酰胺类选择性BCL-2抑制剂